Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 07 Dec 2022
Tukysa (tucatinib) reimbursed in British Columbia for the treatment of patients with advanced or metastatic HER2 positive breast cancer
6 December 2022 - BC is the third province to add Tukysa to its provincial dormulary. ...
Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 24 Feb 2022
AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...
Posted by Michael Wonder on 12 Jun 2019
New drug helps extend survival rate of men with advanced prostate cancer: B.C. Cancer Agency study
10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, ...